Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$19.47 -2.8%	$18.23	$16.10 ▼ $41.94	$2.52B	0.67	2.37 million shs	1.84 million shs
AVIR Atea Pharmaceuticals	$3.36 -2.9%	$3.22	$2.46 ▼ $4.15	$296.11M	0.25	328,906 shs	345,776 shs
LEGN Legend Biotech	$41.59 -1.3%	$33.61	$27.34 ▼ $60.87	$7.74B	0.19	1.37 million shs	1.46 million shs
NKTR Nektar Therapeutics	$24.94 -6.5%	$15.43	$6.48 ▼ $37.38	$330.89M	0.94	521,697 shs	1.10 million shs
TPTX Turning Point Therapeutics	$76.01	$75.83	$23.77 ▼ $82.20	$3.81B	-0.18	1.14 million shs	4,322 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	+1.47%	+2.61%	+12.84%	+10.11%	-49.25%
AVIR Atea Pharmaceuticals	-0.86%	-8.47%	+7.79%	+16.50%	-10.59%
LEGN Legend Biotech	+5.99%	+6.09%	+21.41%	+28.45%	-23.40%
NKTR Nektar Therapeutics	+10.48%	+6.25%	+205.50%	+179.38%	+22.62%
TPTX Turning Point Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.3305 of 5 stars	4.3	0.0	0.0	4.4	2.7	2.5	0.6
AVIR Atea Pharmaceuticals	2.781 of 5 stars	3.3	1.0	0.0	0.0	3.2	2.5	1.3
LEGN Legend Biotech	3.5835 of 5 stars	4.5	3.0	0.0	0.0	2.9	1.7	0.6
NKTR Nektar Therapeutics	4.0678 of 5 stars	3.4	2.0	0.0	4.2	3.1	2.5	0.0
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.00	105.44% Upside
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	78.57% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$73.33	76.32% Upside
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	254.18% Upside
TPTX Turning Point Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TPTX, APLS, NKTR, LEGN, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/17/2025	LEGN Legend Biotech	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/17/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/10/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$80.00 ➝ $81.00
7/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
7/2/2025	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00 ➝ $54.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	3.13	N/A	N/A	$1.84 per share	10.58
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$5.20 per share	N/A
LEGN Legend Biotech	$627.24M	12.18	N/A	N/A	$5.70 per share	7.30
NKTR Nektar Therapeutics	$98.43M	3.14	N/A	N/A	$4.94 per share	5.05
TPTX Turning Point Therapeutics	$30.83M	123.46	N/A	N/A	$15.84 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	0.00	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
AVIR Atea Pharmaceuticals	-$168.38M	-$1.65	0.00	N/A	N/A	N/A	-31.26%	-29.27%	8/6/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	0.00	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
NKTR Nektar Therapeutics	-$118.96M	-$9.60	0.00	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)
TPTX Turning Point Therapeutics	-$236.55M	-$6.90	N/A	N/A	N/A	N/A	-37.45%	-35.62%	N/A

Latest TPTX, APLS, NKTR, LEGN, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NKTR Nektar Therapeutics	-$2.58	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	LEGN Legend Biotech	-$0.18	N/A	N/A	N/A	$237.49 million	N/A
8/7/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
AVIR Atea Pharmaceuticals	N/A	19.94	19.94
LEGN Legend Biotech	0.30	5.20	5.07
NKTR Nektar Therapeutics	N/A	3.24	3.24
TPTX Turning Point Therapeutics	N/A	16.83	16.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
AVIR Atea Pharmaceuticals	86.67%
LEGN Legend Biotech	70.89%
NKTR Nektar Therapeutics	75.88%
TPTX Turning Point Therapeutics	90.33%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
AVIR Atea Pharmaceuticals	18.10%
LEGN Legend Biotech	0.02%
NKTR Nektar Therapeutics	5.25%
TPTX Turning Point Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	70.09 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable
TPTX Turning Point Therapeutics	250	50.07 million	45.77 million	Not Optionable

TPTX, APLS, NKTR, LEGN, and AVIR Headlines

Recent News About These Companies

Turning Point Therapeutics Inc (TPTX) - Investing.com

June 26, 2025 | investing.com

BMS sets up Roche, Pfizer rivalry with Turning Point takeover

May 20, 2025 | pharmaphorum.comP

Digging Into Turning Point USA’s Role in the Trump 2024 Ground Game

October 8, 2024 | talkingpointsmemo.comT

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance

September 29, 2024 | markets.businessinsider.com

Digital therapeutics at a turning point: What we heard at DTx East

September 14, 2024 | pharmaphorum.comP

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

August 9, 2024 | seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

August 6, 2024 | seekingalpha.com

Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript

July 25, 2024 | seekingalpha.com

Glass System in Turning Point Residence

April 2, 2024 | archdaily.comA

Bid to remove prosecutors sets up turning point in Trump’s Georgia case

February 19, 2024 | politico.comP

Turning Point Brands Inc.

February 17, 2024 | wsj.com

Alzheimer’s: A Turning Point?

February 12, 2024 | bbc.co.uk

Turning Point Brands Inc (TPB)

February 10, 2024 | investing.com

Cormorant Asset Management, LP's Net Worth

February 10, 2024 | benzinga.com

Solving quadratic equations - Edexcel

January 15, 2024 | bbc.co.uk

COP15: A Turning Point for Investor Approaches to Biodiversity

December 19, 2023 | morningstar.comM

Turning Point USA: Are conservatives fighting back on campus?

December 16, 2023 | bbc.comB

BMS bet looking good as Augtyro approved in ROS1-positive NSCLC

November 16, 2023 | thepharmaletter.comT

PhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in blood

October 29, 2023 | ulster.ac.ukU

A Turning Point for Japan-US Climate Cooperation?

October 28, 2023 | thediplomat.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

TPTX, APLS, NKTR, LEGN, and AVIR Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$19.47 -0.57 (-2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$19.97 +0.50 (+2.57%)

As of 07:46 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Atea Pharmaceuticals NASDAQ:AVIR

$3.36 -0.10 (-2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 0.00 (0.00%)

As of 04:09 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Legend Biotech NASDAQ:LEGN

$41.59 -0.54 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$41.70 +0.11 (+0.28%)

As of 07:16 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Nektar Therapeutics NASDAQ:NKTR

$24.94 -1.73 (-6.49%)

Closing price 04:00 PM Eastern

Extended Trading

$24.62 -0.33 (-1.30%)

As of 07:59 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time